Caricamento...
Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with...
Salvato in:
| Pubblicato in: | Intern Med |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The Japanese Society of Internal Medicine
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7008039/ https://ncbi.nlm.nih.gov/pubmed/31534079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.2597-18 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|